Hontecillas-Prieto, L., García-Domínguez, D. J., Palazón-Carrión, N., Martín García-Sancho, A., Nogales-Fernández, E., Jimenez Cortegana, C., . . . Cruz Merino, L. d. l. (2024). CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Citación estilo ChicagoHontecillas-Prieto, Lourdes, Daniel J. García-Domínguez, Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, Carlos Jimenez Cortegana, Eduardo Ríos Herranz, Víctor Sánchez Margalet, y Luis de la Cruz Merino. CD8+ NKs As a Potential Biomarker of Complete Response and Survival With Lenalidomide Plus R-GDP in the R2-GDP-GOTEL Trial in Recurrent/refractory Diffuse Large B Cell Lymphoma. 2024.
Cita MLAHontecillas-Prieto, Lourdes, et al. CD8+ NKs As a Potential Biomarker of Complete Response and Survival With Lenalidomide Plus R-GDP in the R2-GDP-GOTEL Trial in Recurrent/refractory Diffuse Large B Cell Lymphoma. 2024.